stockrow
Saturday 7 November 2026
Export GRI’s income statement to Excel — free account
GRI Bio, Inc.
- EPS
- +97.5%
- Free cash flow
- +54.3%
Quarter to June 2026, against a year earlier
1.84
0.29
+18.71%
Follow GRI
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 0 | — | — | — | — | — | — | — | 133 | — | — | — | |
| Gross margin, % | — | — | 0.00 | 0.00 | 100.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | (4) | (3) | (5) | (9) | (3) | (13) | (8) | (12) | (10) | +15.7% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | (4,822.00) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | (4) | (3) | (5) | (9) | (3) | (13) | (8) | (12) | (10) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (19.00) | (0.98) | (1.07) | (1.42) | (898,257.30) | (140,562.80) | (1,546.50) | (121.80) | (51.57) | +30.4% | ||||||
| Cash flow | — | — | (10.44) | (0.81) | (0.82) | (1.27) | 0.00 | (89,900.00) | (1,324.77) | (103.73) | (5.77) | +38.8% | ||||||
| Capex | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (80.00) | 0.00 | (0.03) | 0.00 | n/m | ||||||
| Free cash flow | — | — | (10.44) | (0.81) | (0.82) | (1.27) | 0.00 | (89,980.00) | (1,324.77) | (103.76) | (5.77) | +38.8% | ||||||
| Book value | — | — | 0.67 | 0.91 | (0.32) | 0.89 | 0.00 | 2,590.00 | 620.31 | 61.18 | 5.70 | +90.4% | ||||||
| Shares, m | — | — | 0 | 4 | 5 | 7 | 0 | 0 | 0 | 0 | 1 | (11.3%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | — | — | — | — | — | 0.00 | — | |||||
| P/S | — | — | — | — | 0.00 | — | — | — | — | — | 0.00 | — | ||||||
| P/B | — | — | — | — | 0.00 | — | — | — | — | — | 0.32 | — | ||||||
| EV/Sales | — | — | — | — | 0.00 | — | — | — | — | — | 0.00 | — | ||||||
| EV/FCF | — | — | — | — | (11,878,707.71) | — | — | — | — | — | 0.72 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (2) | (3) | (4) | (8) | (1) | (9) | (9) | (10) | (10) | +23.2% | |||||
| Capex | — | — | 0 | — | 0 | — | 0 | 0 | — | 0 | 0 | +4.5% | ||||||
| Free cash flow | — | — | (2) | (3) | (4) | (8) | (1) | (9) | (9) | (10) | (10) | +23.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 0 | 3 | (2) | 6 | (2) | 0 | 4 | 6 | 10 | +69.0% | |||||
| Net debt | — | — | (1) | (4) | 0 | (8) | 0 | (2) | (5) | (8) | (11) | +44.9% | ||||||
| Shareholders’ equity | — | — | 0 | 3 | (1) | 6 | (2) | 0 | 4 | 6 | 10 | +69.0% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (1,349.37) | (140.95) | (184.36) | (200.28) | (73.80) | (780.89) | (232.73) | (166.00) | (113.27) | +1,183.4 pt | |||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | (256.19) | (205.77) | (547.95) | (426.35) | (153.45) | 1,908.78 | (471.59) | (238.17) | (142.02) | +18.0 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 2 | 2 | 3 | 2 | 4 | 4 | 4 | — | +12.2% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2020 · latest quarter Mar 2020 · fundamentals updated 26 Oct 2026
GRI Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CVKD Cadrenal Therapeutics, Inc. | $3.6M | — (loss-making) | — | — | n/m | +26.24% (above 0%: growing) | 0.00% | 0.00% | Compare |
| LIMN Liminatus Pharma Inc. | $3.5M | — (loss-making) | — | — | n/m | +89.00% (above 0%: growing) | — | 0.00% | Compare |
| GRI GRI Bio, Inc. | $3.4M | — (loss-making) | — (loss-making) | — | n/m | +54.33% (above 0%: growing) | 0.00% | 0.00% | |
| LIPO Lipella Pharmaceuticals Inc. | $3.4M | — (loss-making) | — (loss-making) | −36.44% (below 0%: shrinking) | n/m | −41.79% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| TRAW Traws Pharma, Inc. | $3.4M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −25.51% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PBLA Panbela Therapeutics Inc. | $3.4M | — (loss-making) | — | — | n/m | +66.23% (above 0%: growing) | — | 0.00% | Compare |
| ONCO Onconetix, Inc. | $3.2M | — (loss-making) | — (loss-making) | −83.94% (below 0%: shrinking) | n/m | −36.00% (below 0%: shrinking) | 25.15% | (15,969.59%) | Compare |
| SXTP 60 Degrees Pharmaceuticals Inc. | $3.2M | — (loss-making) | — (loss-making) | −32.48% (below 0%: shrinking) | n/m | −54.33% (below 0%: shrinking) | 27.32% | (1,092.40%) | Compare |
| ADXN Addex Therapeutics Ltd. Sponsored ADR | $3.1M | — (loss-making) | — (loss-making) | −85.95% (below 0%: shrinking) | n/m | −2.73% (below 0%: shrinking) | (2.67%) | 0.00% | Compare |
| Median of peers | $3.4M | — | — | −83.94% | — | −14.12% | 12.58% | 0.00% |
Pay and ownership Proxy statement filed 28 September 2026
Ownership
Directors and executive officers, together
less than 1%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement